Enanta Pharmaceuticals Stock News

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) stock surges 12.45% (As on Nov 23, 11:57:54 AM UTC-4, Source: Google Finance) after the company posted mixed results for the The post Enanta Pharmaceuticals Inc (NASDAQ:ENTA) beaten the earnings estimates appeared first on FXDailyReport.Com .

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) gapped up before the market opened on Tuesday . The stock had previously closed at $75.18, but opened at $77.96. Enanta Pharmaceuticals shares last traded at $81.51, with a volume of 797 shares changing hands. A number of research analysts have weighed in on ENTA shares. Robert W. Baird []

The stock price of Enanta Pharmaceuticals Inc (NASDAQ: ENTA) increased by over 10% during intraday trading today. This is why it happened.

Enanta Pharmaceuticals, Inc. (ENTA) has reported mixed results for the fourth quarter of Fiscal Year 2021 (ended September 30, 2021). The post Enantas Q4 Loss Meets Expectations appeared first on Smarter Analyst .

Wall Street brokerages expect that Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will announce earnings of ($1.31) per share for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Enanta Pharmaceuticals earnings. The highest EPS estimate is ($0.60) and the lowest is ($1.59). Enanta Pharmaceuticals posted earnings of ($0.55) per share during the same quarter []

ENTA earnings call for the period ending September 30, 2021.

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 6.87% and 33.87%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the sto

Enanta Pharmaceuticals, Inc. (ENTA) CEO Dr. Jay Luly on Q4 Fiscal 2021 Result - Earnings Call Transcript

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 6.87% and 33.87%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the sto

Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reportin

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) was the recipient of a large decline in short interest in October. As of October 29th, there was short interest totalling 1,080,000 shares, a decline of 32.1% from the October 14th total of 1,590,000 shares. Currently, 6.1% of the shares of the stock are short sold. Based on an average daily []

Enanta Pharmaceuticals (NASDAQ:ENTA) had its price target cut by JMP Securities from $121.00 to $111.00 in a research report sent to investors on Friday, Price Targets.com reports. They currently have a market outperform rating on the biotechnology companys stock. Several other analysts have also issued reports on the stock. Zacks Investment Research lowered shares of []